Perspectives of γδ T Cells in Tumor Immunology

Cancer Research - Tập 67 Số 1 - Trang 5-8 - 2007
Dieter Kabelitz1, Daniela Wesch2, Wei He3
1Institute of Immunology, University Hospital Schleswig-Holstein Campus Kiel, Michaelisstrasse 5, D-24105 Kiel, Germany
21Institute of Immunology, University Hospital Schleswig-Holstein Campus Kiel, Kiel, Germany and
32Department of Immunology, Chinese Academy of Medical Sciences and School of Basic Medicine, Peking Union Medical College, Beijing, P.R. China

Tóm tắt

Abstract Subsets of human γδ T cells recognize tumor cell–expressed ligands that are not seen by the T-cell receptor of conventional αβ T cells. Vδ1 T cells recognize MHC class I chain–related molecules A and B and UL-16–binding proteins expressed at variable levels on epithelial tumor cells and some leukemias and lymphomas. In addition, therapeutically used aminobisphosphonates and synthetic phosphoantigens activate Vδ2 T cells, the dominant subset of γδ T cells in human peripheral blood that display strong cytotoxicity towards various epithelial tumors. Intentional activation of γδ T cells in vivo and/or adoptive cell therapy with in vitro expanded γδ T cells holds considerable promise as a novel immunotherapy in certain types of cancer. [Cancer Res 2007;67(1):5–8]

Từ khóa


Tài liệu tham khảo

Hayday AC. γδ T cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol 2000; 18: 975–1026.

Girardi M, Oppenheim DE, Steele CR, et al. Regulation of cutaneous malignancy by γδ T cells. Science 2001; 294: 605–9.

Bonneville M, Scotet E. Human Vγ9Vδ2 T cells: promising new leads for immunotherapy of infections and tumors. Curr Opin Immunol 2006; 18: 1–8.

Maeurer MJ, Martin D, Walter W, et al. Human intestinal Vδ1+ T lymphocytes recognize tumor cells of epithelial origin. J Exp Med 1996; 183: 1681–96.

Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. Broad tumor-associated expression and recognition by tumor-derived γδ T cells of MIC-A and MIC-B. Proc Natl Acad Sci U S A 1999; 96: 6879–84.

Poggi A, Venturino C, Catellani S, et al. Vδ1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid. Cancer Res 2004; 64: 9172–9.

Wu J, Groh V, Spies T. T cell antigen receptor engagement and specificity in the recognition of stress-inducible MHC class I-related chains by human epithelial γδ T cells. J Immunol 2002; 169: 1236–40.

Zhao J, Huang J, Chen H, Cui L, He W. Vδ1 T cell receptor binds specifically to MHC I chain related A: molecular and biochemical evidences. Biochem Biophys Res Commun 2006; 339: 232–40.

Viey E, Fromont G, Escudier B, et al. Phosphostim-activated γδ T cells kill autologous metastatic renal cell carcinoma. J Immunol 2005; 174: 1338–47.

Gober HJ, Kistowska M, Angman L, Jenö P, Mori L, De Libero G. Human T cell receptor γδ T cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 2003; 197: 163–8.

Kunzmann V, Bauer E, Feurle J, Weiβinger F, Torny HP, Wilhelm M. Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000; 86: 384–92.

Corvaisier M, Moreau-Aubry A, Diez E, et al. Vγ9Vδ2 T cell response to colon carcinoma cells. J Immunol 2005; 175: 5481–8.

Scotet E, Martinez LO, Grant E, et al. Tumor recognition following Vγ9Vδ2 T cell receptor interactions wit a surface F1-ATPase-related structure and apolipoprotein A-I. Immunity 2005; 22: 71–80.

Xu C, Zhang H, Hu H, et al. γδ T cells recognize tumor cells via CDR3δ region. Mol Immunol 2007; 44: 302–10.

Das H, Groh V, Kuijl C, et al. MICA engagement by human Vγ2Vδ2 T cells enhances their antigen-dependent effector function. Immunity 2001; 15: 83–93.

Rincon-Orozco B, Kunzmann V, Wrobel P, Kabelitz D, Steinle A, Herrmann T. Activation of Vγ9Vδ2 T cells by NKG2D. J Immunol 2005; 175: 2144–51.

Kabelitz D, Pitters E, Wesch D, Zöller M. Characterization of tumor reactivity of human Vγ9Vδ2 γδ T-cells in vitro and in severe combined immunodeficiency mice in vivo. J Immunol 2004; 173: 6767–76.

Viey E, Laplace C, Escudier B. Peripheral γδ T-lymphocytes as an innovative tool in immunotherapy for metastatic renal cell carcinoma. Expert Rev Anticancer Ther 2005; 5: 973–86.

Märten A, von Lilienfeld-Toal M, Büchler MW, Schmidt J. Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing γδ T cell cytotoxicity. Int J Cancer 2006; 119: 2359–65.

Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006; 6: 295–307.

Thông tin
Thông tin xuất bản

Cancer Research

Tập 67 Số 1

5-8

Thông tin tác giả